{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Personalis, Inc. Hits New 52-Week High of $8.70, Up 557.58%
Personalis, Inc., a microcap in the Pharmaceuticals & Biotechnology sector, achieved a new 52-week high of USD 8.70 on October 8, 2025, reflecting a significant performance improvement. The company has seen a 557.58% stock increase over the past year, despite being loss-making and having a market cap of USD 472 million.
Is Personalis, Inc. technically bullish or bearish?
As of September 11, 2025, Personalis, Inc. shows a bullish technical trend overall, despite mixed short-term signals and underperformance compared to the S&P 500.
Is Personalis, Inc. technically bullish or bearish?
As of June 2, 2025, Personalis, Inc. shows a mildly bullish trend overall, supported by positive MACD and Bollinger Bands indicators, but caution is advised due to a bearish weekly RSI and mixed signals from daily moving averages.
Who are in the management team of Personalis, Inc.?
As of March 2022, the management team of Personalis, Inc. includes Jonathan MacQuitty (Independent Chairman), John West (CEO), and several Independent Directors: Patrick Balthrop, A. Blaine Bowman, Alan Colowick, Karin Eastham, and Kenneth Ludlum. They oversee the company's strategic direction and operations.
What does Personalis, Inc. do?
Personalis, Inc. is a cancer genomics company that provides molecular data to develop personalized cancer therapies. As of March 2025, it reported net sales of $21 million and a net loss of $16 million, with a market cap of $550.27 million.
How big is Personalis, Inc.?
As of Jun 18, Personalis, Inc. has a market capitalization of 550.27 million and reported net sales of 85.70 million with a net profit of -84.07 million over the latest four quarters. Shareholder's funds are 202.96 million, and total assets amount to 270.27 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
